Stockreport

SynOx Therapeutics Receives Fast Track Designation from U.S. Food and Drug Administration for Emactuzumab for Tenosynovial Giant Cell Tumours (TGCT) [Yahoo! Finance]

ROCHE HOLDING LTD S/ADR  (RHHBY) 
NASDAQ:AMEX Investor Relations: roche.com/investors.htm
PDF biopharmaceutical company developing of emactuzumab for Tenosynovial Giant Cell Tumours (TGCT), today announced that the United States Food and Drug Administration (FDA) [Read more]